Details for New Drug Application (NDA): 022369

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

NDA 022369 describes LATISSE, which is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the LATISSE profile page.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

Summary for 022369

Tradename:	LATISSE
Applicant:	Allergan
Ingredient:	bimatoprost
Patents:	8

Pharmacology for NDA: 022369

Medical Subject Heading (MeSH) Categories for 022369

Antihypertensive Agents

Suppliers and Packaging for NDA: 022369

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369	NDA	Allergan, Inc.	0023-3616	0023-3616-05	1 BOTTLE, DROPPER in 1 CARTON (0023-3616-05) / 5 mL in 1 BOTTLE, DROPPER
LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369	NDA	Allergan, Inc.	0023-3616	0023-3616-70	1 BOTTLE, DROPPER in 1 CARTON (0023-3616-70) / 3 mL in 1 BOTTLE, DROPPER

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION/DROPS;TOPICAL			Strength	0.03%
Approval Date:	Dec 24, 2008	TE:	AT	RLD:	Yes
Patent:	See Plans and Pricing	Patent Expiration:	Aug 25, 2023	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
Patent:	See Plans and Pricing	Patent Expiration:	May 25, 2024	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF INCREASING HAIR GROWTH
Patent:	See Plans and Pricing	Patent Expiration:	May 25, 2024	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD OF STIMULATING HAIR GROWTH

Expired US Patents for NDA 022369

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	See Plans and Pricing	See Plans and Pricing
Allergan	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	See Plans and Pricing	See Plans and Pricing
Allergan	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	See Plans and Pricing	See Plans and Pricing
Allergan	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	See Plans and Pricing	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.